- Latest available (Revised)
- Point in Time (17/11/2004)
- Original (As made)
Version Superseded: 30/10/2005
Point in time view as at 17/11/2004.
There are currently no known outstanding effects for the The Medicines (Products for Animal Use—Fees) Regulations 2004 (revoked), PART 4.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
1. The application fee for a variation to a marketing authorisation of a type specified in the table below is that specified opposite it.U.K.
Type of variation | Fee (£) | |
---|---|---|
1 | Change following modification(s) to the manufacturing authorisation | 620 |
2 | Change in the name of the medicinal product (either invented name or common name) | 620 |
3 | Change in the name and/or address of the marketing authorisation holder | 240 |
4 | Replacement of an excipient with a comparable excipient (excluding adjuvants for vaccines and biologically derived excipients) | 620 |
5 | Change in the colouring system of the product (addition, deletion or replacement of colourant(s)) | 620 |
6 | Change in the flavouring system of the product (addition, deletion or replacement of flavour(s)) | 620 |
7 | Change in coating weight of tablets or change in weight of capsule shells | 620 |
8 | Change in the qualitative composition of immediate packaging material | 620 |
9 | Deletion of an indication | 620 |
10 | Deletion of a route of administration | 620 |
11 | Addition or replacement of measuring device for dosage forms | 620 |
12 | Change in the manufacturer(s) of active substance | 620 |
13 | Change in name of manufacturer of active substance | 240 |
14 | Change in supplier of intermediate compound used in the manufacture of the active substance | 620 |
15 | Minor change of manufacturing process of the active substance | 620 |
16 | Change in specification of starting material or intermediate used in the manufacture of the active substance | 620 |
17 | Change in batch size of active substance | 620 |
18 | Change in specification of active substance | 620 |
19 | Minor change in manufacture of the medicinal product | 620 |
20 | Change in in-process controls applied during the manufacture of the product | 620 |
21 | Change in the batch size of finished product | 620 |
22 | Change in specification of the medicinal product | 620 |
23 | Synthesis or recovery of non-pharmacopoeial excipients which had been described in the original dossier | 620 |
24 | Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 620 |
25 | Extension of shelf life as foreseen at time of authorisation | 620 |
26 | Extension of the shelf life or retest period of the active substance | 620 |
27 | Change in shelf life after first opening | 620 |
28 | Change in shelf life after reconstitution | 620 |
29 | Change in the storage conditions | 620 |
30 | Change in test procedure of active substance | 620 |
31 | Change in test procedure for a starting material or intermediate used in the manufacture of the active substance | 620 |
32 | Change in the test procedures of the medicinal product | 620 |
33 | Changes to comply with supplements to pharmacopoeias | 620 |
34 | Change in test procedures of non-pharmacopoeial excipients | 620 |
35 | Change in test procedure of immediate packaging | 620 |
36 | Change in test procedure of administrative device | 620 |
37 | Change in pack size for a medicinal product | 620 |
38 | Change in container shape | 620 |
39 | Change of imprints, bossing or other markings (except scoring) on tablets or printing on capsules, including addition or changes of inks used for product marking | 620 |
40 | Change of dimensions of tablets, capsules, suppositories or pessaries without change of quantitive composition and mean mass | 620 |
41 | Change in the manufacturing process of a non proteinaceous component due to the subsequent introduction of a biotechnology step | 620 |
2. The application fee for any other variation to a marketing authorisation (other than a mutually recognised marketing authorisation), or for any variation to a product licence, shall be £2,460 save as provided in the table below.U.K.
Type of variation | Fee (£) | |
---|---|---|
1 | Change made simultaneously as a change made to another product by the same marketing authorisation holder where the changes are identical and there is identical supporting data | 240 |
2 | Change of distributor where no other aspects of the dossier are changed and the marketing authorisation holder remains the same | 240 |
3 | Change of marketing authorisation holder where no other aspects of the dossier are changed | 240 |
4 | Simple dosage instruction changes where the change is not the result of safety concerns, no new studies are required to support the change and the dose in mg/kg body weight remains the same | 620 |
5 | Addition or change to user safety warnings where no other aspects of the dossier are changed, no user safety warnings are removed, no new studies are required to support the change and the proposed warnings serve to increase the protection of the user | 620 |
6 | Corrections or simple text layout changes to summary of product characteristics and/or product literature where the changes are not a result of safety concerns, no new studies are required to support the change and no other aspects of the dossier are changed | 620 |
7 | Any change to a licence relating solely to an emergency vaccine | 40 |
3.—(1) The fee for an application for the variation of a mutually recognised marketing authorisation shall, in respect of each individual variation to which the application relates, be that specified in the table below.U.K.
(2) In the table, “connected variation” means a variation to which sub-paragraph (1) applies made simultaneously or after a variation application for another such authorisation for which a fee is paid in pursuance of sub-paragraph (1), and where, for both applications the data relied upon and the applicant is the same.
Mutually recognised marketing authorisation variation type | Fee—United Kingdom acting as the Reference Member State (£) | Fee—United Kingdom not acting as the Reference Member State (£) |
---|---|---|
Type IA notification | 1,590 | 240 |
Type IB | 2,615 | 240 |
Type II | 9,145 | 2,460 |
Variation with extras | 10,460 | 4,375 |
Connected variation | 1,590 | 240 |
4. The fee for an application for the variation of a manufacturer’s licence is £150 for each individual variation save that the fee is—U.K.
(a)£110 in respect of a licence to which paragraph 4(2) of Part 2 of this Schedule applies;
(b)£445 where scientific or pharmaceutical assessment is required.
5. The fee for an application for a variation of a wholesale dealer’s licence is £150 for each individual variation save that the fee is £445 where scientific or pharmaceutical assessment is required.U.K.
6. The fee for an application for the variation of an animal test certificate is £240 in respect of each individual variation.U.K.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: